Second Time A Charm? Enzon Sells Biotech Business To Italian Pharma
This article was originally published in The Pink Sheet Daily
One year after a failed effort to sell off its biotech business, Enzon will bring in $300 million by selling its four specialty drugs to Sigma-Tau.
You may also be interested in...
Complete response letter for Acacia’s Barhemsys is only rain on Oct. 5 approval parade.
Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.
Shareholder activist hedge fund calls a “Town Hall” to justify ousting the CEO as part of an unusual maneuver to solicit shareholder votes.